Stock data
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC) reported revenue of US$35.95M and net income of -US$104.99M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$35.95M | — | -US$115.22M | -US$104.99M | — |
| 2024 | US$35.58M | — | -US$119.61M | -US$105.32M | — |
| 2023 | US$20.76M | — | -US$139.03M | -US$132.49M | — |
| 2022 | US$31.10M | — | -US$129.53M | -US$128.18M | — |
| 2021 | US$45.78M | — | -US$82.13M | -US$83.89M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$6.64M | -US$23.64M | — |
| 2026-03-31 | US$6.15M | -US$25.13M | — |
| 2025-12-31 | US$11.02M | -US$20.49M | — |
| 2025-09-30 | US$11.23M | -US$32.17M | — |
| 2025-06-30 | US$6.46M | -US$26.02M | — |
| 2025-03-31 | US$7.24M | -US$26.32M | — |
| 2024-12-31 | US$5.18M | -US$34.57M | — |
| 2024-09-30 | US$15.36M | -US$24.67M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.